1,196.60
price up icon0.71%   10.73
 
loading
Lilly Eli Co stock is traded at $1,196.60, with a volume of 1.52M. It is up +0.71% in the last 24 hours and up +6.89% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,185.87
Open:
$1194.35
24h Volume:
1.52M
Relative Volume:
0.49
Market Cap:
$1.07T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
43.07
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+1.29%
1M Performance:
+6.89%
6M Performance:
+12.21%
1Y Performance:
+48.28%
1-Day Range:
Value
$1,187.50
$1,206.94
1-Week Range:
Value
$1,139.00
$1,206.94
52-Week Range:
Value
$623.78
$1,249.45

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
50,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2026-08-05
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY vs JNJ, ABBV, MRK, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LLY icon
LLY
Lilly Eli Co
1,196.30 1.06T 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
263.31 624.12B 97.93B 21.04B 17.80B 8.6278
ABBV icon
ABBV
Abbvie Inc
258.95 453.92B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
131.18 322.26B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
154.85 296.78B 54.66B 13.58B 16.05B 7.0171

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-17-26 Downgrade HSBC Securities Hold → Reduce
Feb-25-26 Initiated RBC Capital Mkts Outperform
Feb-20-26 Initiated Barclays Overweight
Jan-07-26 Resumed UBS Buy
Dec-16-25 Upgrade Daiwa Securities Neutral → Buy
Dec-15-25 Reiterated BofA Securities Buy
Dec-15-25 Reiterated Goldman Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-10-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-20-25 Reiterated BMO Capital Markets Outperform
Oct-14-25 Upgrade Erste Group Hold → Buy
Sep-17-25 Downgrade Berenberg Buy → Hold
Aug-27-25 Upgrade HSBC Securities Reduce → Hold
Aug-18-25 Downgrade Daiwa Securities Outperform → Neutral
Aug-07-25 Downgrade Leerink Partners Outperform → Market Perform
Jun-05-25 Downgrade Erste Group Buy → Hold
Apr-28-25 Downgrade HSBC Securities Buy → Reduce
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
11:35 AM

Novo Nordisk seeks preliminary injunction days after suing Eli Lilly - MobiHealthNews

11:35 AM
pulisher
10:29 AM

Novo Nordisk Seeks Pause on Eli Lilly’s Weight Loss Drug Ads - Bloomberg Law News

10:29 AM
pulisher
10:08 AM

Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal - Endpoints News

10:08 AM
pulisher
09:42 AM

Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads - PharmaLive

09:42 AM
pulisher
07:56 AM

Novo Nordisk seeks injunction to block Eli Lilly weight loss drug ads - Yahoo Finance

07:56 AM
pulisher
06:51 AM

Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads - Yahoo Finance

06:51 AM
pulisher
06:01 AM

The legal battle continues – Novo now seeks a temporary ban on Eli Lilly's advertisements - medwatch.com

06:01 AM
pulisher
06:00 AM

This Billionaire Made $360 Million Selling His Psychedelic Company To Eli Lilly - Forbes

06:00 AM
pulisher
05:13 AM

Novo Nordisk seeks court order to halt Eli Lilly drug ads - Investing.com Nigeria

05:13 AM
pulisher
04:47 AM

Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads - Yahoo Finance UK

04:47 AM
pulisher
04:33 AM

LLY|Eli Lilly and Co|Price:1200.970|Chg%:+15.100 - TradingKey

04:33 AM
pulisher
04:15 AM

Novo Investors: Lawsuit against Eli Lilly is apt - medwatch.com

04:15 AM
pulisher
03:42 AM

Eli Lilly stock holds after 2025 revenue and profit growth - Ad-hoc-news.de

03:42 AM
pulisher
12:30 PM

2 Top Growth Stocks to Buy Right Now Without Any Hesitation - The Motley Fool

12:30 PM
pulisher
Jul 23, 2026

Novo Nordisk’s fight against Eli Lilly has gone legal: A top lawyer evaluates the case - Business Post

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly and Company Price Today | XLLY Live Price, Chart & Market Cap - OKX

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly Reports Positive Results from Two Phase III Trials | PharmExec - Pharmaceutical Executive

Jul 23, 2026
pulisher
Jul 23, 2026

Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Advertising Claims - Law Commentary

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly (NYSE:LLY) Shapes the Healthcare Earnings Narrative - Kalkine Media

Jul 23, 2026
pulisher
Jul 23, 2026

Lilly Targets Early 2027 Filing for Next Obesity Drug - Yahoo Finance

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly's Retatrutide Clears Two More Trials Ahead of 2027 Filing - Yahoo Finance

Jul 23, 2026
pulisher
Jul 23, 2026

Lilly, with new data, to seek FDA approval of obesity drug retatrutide - BioPharma Dive

Jul 23, 2026
pulisher
Jul 23, 2026

Lilly to file for next-gen obesity drug approval in early 2027 - Yahoo Finance

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly (NYSE:LLY) Growth & Technical Setup Signal A Key Market Test - Kalkine Media

Jul 23, 2026
pulisher
Jul 23, 2026

Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data - BioSpace

Jul 23, 2026
pulisher
Jul 23, 2026

Lilly Endowment reports 90.4M Eli Lilly (LLY) shares, a 9.6% stake - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results? - Yahoo Finance UK

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average - Forbes

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly Delay Puts Madrigal Stock In Focus For Obesity Drug Investors - simplywall.st

Jul 23, 2026
pulisher
Jul 23, 2026

Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application - Reuters

Jul 23, 2026
pulisher
Jul 23, 2026

Novo Nordisk Lawsuit Against Eli Lilly: Wegovy Maker Alleges Misleading Zepbound, Mounjaro Ads - Stocktwits

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly’s Next-Generation Weight-Loss Shot Clears Another Hurdle - Bloomberg.com

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly (LLY) Advances Next-Gen Weight-Loss Therapy with Promi - GuruFocus

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly presents positive safety data but postpones weight-loss candidate application - medwatch.com

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly to File FDA Approval for Retatrutide in 2027 After Five Positive Phase 3 Trials - MLQ.ai

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly and Co.'s next-generation obesity drug has had its market application delayed until 2027. - 富途牛牛

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly (LLY) Reports Positive Phase 3 Trial Results for Retat - GuruFocus

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly to seek obesity drug approval in Q1 2027 - Breakingthenews.net

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly to seek approval for powerful new obe... - Pluang

Jul 23, 2026
pulisher
Jul 23, 2026

Lilly’s retatrutide meets endpoints in two phase 3 obesity trials - Investing.com

Jul 23, 2026
pulisher
Jul 23, 2026

New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit - STAT

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data - WSJ

Jul 23, 2026
pulisher
Jul 23, 2026

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C - Eli Lilly and Company

Jul 23, 2026
pulisher
Jul 23, 2026

Eli Lilly (NYSE:LLY) Shows Strong Growth and Breakout Technical Setup - ChartMill

Jul 23, 2026
pulisher
Jul 22, 2026

Novo Nordisk Sues Eli Lilly Over Wegovy and Mounjaro Obesity Drug Ads - 동아사이언스

Jul 22, 2026
pulisher
Jul 22, 2026

Watch Lilly’s Next-Generation Obesity Shot Clears Another Hurdle - Bloomberg.com

Jul 22, 2026
pulisher
Jul 22, 2026

Whiz Buckley On Eli Lilly’s Psychedelic Takeout - The Dales Report

Jul 22, 2026
pulisher
Jul 22, 2026

Novo Nordisk Sues Rival Eli Lilly Over Advertising - WFXB

Jul 22, 2026
pulisher
Jul 22, 2026

Form 4 Eli lilly For: 22 July By Investing.com - Investing.com Canada

Jul 22, 2026
pulisher
Jul 22, 2026

Novo Nordisk Says Lilly’s ‘Gold Standard’ GLP-1 Comparison Misleads Consumers - Law.com

Jul 22, 2026
pulisher
Jul 22, 2026

Historic Indy estate built for Eli Lilly executive hits market for $7.99 million - WISH-TV

Jul 22, 2026

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
JNJ JNJ
$263.43
price up icon 1.54%
$259.02
price up icon 0.70%
MRK MRK
$131.22
price up icon 0.48%
NVS NVS
$154.97
price down icon 0.69%
AZN AZN
$168.87
price up icon 0.42%
Cap:     |  Volume (24h):